Noxopharm (ASX:NOX) 14-Day RSI: 45.14 (As of Jul. 18, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Noxopharm 14-Day RSI?

Noxopharm ASX:NOX -6.82% 14-Day RSI is 45.14 as of Jul. 18, 2026. The stock has 4 warning signs investors should review. Among 1,424 Biotechnology companies, Noxopharm ranks worse than 66.43% on this metric.

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.

As of today (2026-07-18), Noxopharm's 14-Day RSI is 45.14.

The industry rank for Noxopharm's 14-Day RSI or its related term are showing as below:

ASX:NOX's 14-Day RSI is ranked worse than
66.43% of 1424 companies
in the Biotechnology industry
Industry Median: 47.285 vs ASX:NOX: 45.14

Noxopharm  (ASX:NOX) 14-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.

Noxopharm 14-Day RSI Related Terms

ASX:NOX vs VRTX, REGN, ALNY: 14-Day RSI Comparison

For the Biotechnology subindustry, Noxopharm's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Noxopharm 14-Day RSI vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Noxopharm's 14-Day RSI distribution charts can be found below:

* The bar in red indicates where Noxopharm's 14-Day RSI falls into.


Noxopharm  (ASX:NOX) 14-Day RSI Calculation

The formula for calculating RSI is:

RSI=100–[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 14-Day RSI →
What does a 14-Day RSI of 45.14 mean?
Noxopharm (ASX:NOX) has a 14-Day RSI of 45.14 as of Jul. 18, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Noxopharm and its competitors. According to the industry distribution chart, Noxopharm ranks #946 out of 1424 companies in the Biotechnology industry, placing it in the top 66.4%.
Is Noxopharm's 14-Day RSI too high?
Noxopharm's current 14-Day RSI is 45.14. The Biotechnology industry median 14-Day RSI is 47.29. Noxopharm's value of 45.14 is 4.5% below this industry median. Based on the distribution chart, Noxopharm ranks #946 out of 1424 companies in the Biotechnology industry, which is below the industry midpoint.
How does Noxopharm's 14-Day RSI compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Noxopharm ranks #946 out of 1424 companies for 14-Day RSI. This places Noxopharm in the lower half of its industry. The industry median 14-Day RSI is 47.29. Noxopharm's value of 45.14 is 4.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Biotechnology company?
The median 14-Day RSI among Biotechnology companies is 47.29, based on 1,424 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Noxopharm's current 14-Day RSI of 45.14 is 4.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Noxopharm and its competitors. For the Biotechnology industry, the median 14-Day RSI is 47.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Noxopharm's current 14-Day RSI is 45.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Noxopharm stock overvalued right now?
Noxopharm (ASX:NOX) has a current 14-Day RSI of 45.14. The current 14-Day RSI is 45.14 and 4.5% below the Biotechnology industry median of 47.29. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Noxopharm (ASX:NOX), the current 14-Day RSI is 45.14 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Noxopharm Business Description

Address 60 Linksley Avenue, Glenhaven, NSW, AUS, 2156
Noxopharm Ltd is an Australian clinical-stage drug development company focused on discovering and developing novel treatments for cancer and inflammation, as well as improving mRNA vaccines, based on two preclinical platforms. It is engaged in one segment which is the clinical development in the field of both oncology and non-oncology in the pan-pacific region.